SCHEMBL10322889

SCHEMBL10322889

CN(Cc1ccccc1)C(=O)c1ccc(Cl)c(N)c1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.68
KMT2A Q03164 3/20 0.64
MEN1 O00255 2/20 0.64
ALDH1A1 P00352 3/20 0.55
GAA P10253 1/20 0.55
TSHR P16473 1/20 0.55
HSP90AA1 P07900 1/20 0.54
HTT P42858 1/20 0.54
MAOA P21397 1/20 0.52
KDM4E B2RXH2 1/20 0.51
HDAC1 Q13547 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
MLYCD O95822 1/20 0.50
LIMK2 P53671 3/20 0.49
SIRT2 Q8IXJ6 1/20 0.48
ABL1 P00519 1/20 0.48
LCK P06239 1/20 0.48
LIMK1 P53667 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10324556 0.88 HPGD (0.55) HPGDKMT2AMEN1GAAHSP90AA1
SCHEMBL10322887 0.84 KMT2A (0.61) HPGDKMT2AMEN1ALDH1A1GAA
SCHEMBL11711971 0.82 MEN1 (0.58) HPGDKMT2AMEN1ALDH1A1GAA
SCHEMBL11691195 0.81 KMT2A (0.59) HPGDKMT2AMEN1ALDH1A1HSP90AA1
SCHEMBL19630546 0.79 KMT2A (0.66) HPGDKMT2AMEN1ALDH1A1GAA
SCHEMBL3883126 0.78 KMT2A (0.79) HPGDKMT2AMEN1ALDH1A1GAA
SCHEMBL5644480 0.78 KMT2A (0.79) HPGDKMT2AMEN1ALDH1A1GAA
SCHEMBL3110778 0.78 ALDH1A1 (0.64) HPGDKMT2AMEN1ALDH1A1HTT
SCHEMBL11690587 0.78 KDM4E (0.47) HPGDKMT2AMEN1ALDH1A1GAA
SCHEMBL10318165 0.77 KDM4E (0.50) HPGDKMT2AMEN1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US claimed
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184542-A1 PYRIDO PYRIMIDINES TYMS, TYMP, DPYD HPGD 750/4885KMT2A 2283/4885MEN1 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.